Interleukin-1β induced nuclear factor-κB binds to a disintegrin-like and metalloproteinase with thrombospondin type 1 motif 9 promoter in human chondrosarcoma cells

AYNUR ALTUNTAS[1*], SEVIL OSKAY HALACLI[2*], OZLEM CAKMAK[3], GONUL ERDEN[4], SUMEYYA AKYOL[5], VELI UGURCU[6], SATOSHI HIROHATA[7] and KADIR DEMIRCAN[5]

[1]Division of Chemistry, Ankara Regional Office of Council of Forensic Medicine, Ankara 06100;
[2]Pediatric Immunology Unit, Institute of Children's Health, Hacettepe University, Ankara 06100;
[3]Faculty of Education, Division of Biology Education, Gazi University, Ankara 06500;
[4]Department of Clinical Biochemistry, Medical Faculty, Hacettepe University, Ankara 06100;
[5]Department of Medical Biology, Turgut Ozal University School of Medicine, Ankara 06105;
[6]Department of Medical Biochemistry, Dumlupinar University Medical Faculty, Kutahya 43100, Turkey;
[7]Okayama University Graduate School of Medicine, Dentistry and Pharmacological Sciences, Okayama 700-8558, Japan

Abstract. Nuclear factor-κB (NF-κB) is involved in the regulation of inflammation-associated genes. NF-κB forms dimers which bind with sequences referred to as NF-κB sites (9-11 bp). A disintegrin-like and metalloproteinase with thrombospondin type 1 motif 9 (ADAMTS9) is a type of proteoglycanase, which proteolytically cleaves versican and aggrecan. ADAMTS9 is a cytokine-inducible gene that contains binding sites for NF-κB within its promoter region. Interleukin-1β (IL-1β) affects cartilage metabolism and is involved in the NF-κB pathway. It is therefore hypothesized that NF-κB binding with ADAMTS9 promoters may activate IL-1β, thereby promoting chondrocytic cell growth. In the present study, the OUMS-27 chondrocytic human chondrosarcoma cell line was treated with IL-1β with or without inhibitors of NF-κB signaling pathways. Chromatin immunoprecipitation (ChIP) and electromobility shift assays (EMSA) were conducted order to analyze the binding of NF-κB with the ADAMTS9 promoter region. NF-κB-p65 subunit phosphorylation was promoted in IL-1β-treated cells, which were not treated with inhibitors of NF-κB signaling pathways. By contrast, NF-κB-p65 subunit phosphorylation was inhibited in cells that had been treated with BAY-117085, an NF-κB pathway inhibitor. ChIP and EMSA assays demonstrated that, following treatment with IL-1β, NF-κB-p65 bound to elements located at -1177 and -1335 in the ADAMTS9 promoter region, in contrast to the untreated samples. The results of the present study suggested that NF-κB may be involved in IL-1β-induced activation of ADAMTS9 in human chondrocytes.

Introduction

A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs) are secretory proteins that are involved in a variety of biological processes, such as angiogenesis, cell adhesion, proteolytic shedding and cell signaling. ADAMTS type 1 motif 9 (ADAMTS9) is involved in proteoglycan degradation (1,2). IL-1β was found to induce ADAMTS9 gene expression in OUMS-27 chondrosarcoma cells in a previous investigation (3). ADAMTS9 gene expression was synergistically induced by a combination of IL-1β and tumor necrosis factor α (TNF α), suggesting that the induction of ADAMTS9 may be associated with cartilage inflammation (4). The human ADAMTS9 promoter region contains nuclear factor of activated T cells c1 (NFATc1) consensus sites. Following treatment with IL-1β, NFATc1 was activated in human chondrocytic cells (5). A previous investigation demonstrated that, following treatment with a combination of TNF and IL-1β, the expression of activated activator protein 1 and NF-κB transcription factors was enhanced in human chondrocytic cells (6).

NF-κB is a pro-inflammatory transcription factor, the expression of which is activated by inflammatory cytokines such as TNF α and IL-1, and a number of chemokines (7-9). NF-κB activation may occur via classical or canonical pathways (10). NF-κB is composed of homodimers and heterodimers of five members of the Rel family, which exhibit different binding specificities,

Correspondence to: Dr Kadir Demircan, Department of Medical Biology, Turgut Ozal University School of Medicine, 16/A Gimat, Ankara 06105, Turkey
E-mail: kdemircan1@gmail.com

*Contributed equally

including p65/RelA, RelB, c-Rel, p50/p105 and p52/p100. One of the predominant types of heterodimers consists of p65 and p50 subunits. NF-κB is typically found in the cytoplasm. The nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor (IκB) kinase complex (IKK complex) is composed of two catalytic subunits (IKKα and IKKβ). The IKK complex binds with the regulatory subunit IKKγ/NF-κB essential modulator, which subsequently forms the TNF-α receptor complex, and promotes IκB phosphorylation. Phosphorylated IκB-α is rapidly ubiquitinated and degraded via a proteasome pathway. Degradation of IκB-α leads to the expression of NF-κB, which translocates into the nucleus where it binds to specific binding sites within the promoter regions of target genes (9).

In the present study, the association between NF-κB and IL-1β stimulation was examined, and the involvement of NF-κB and IL-1β in ADAMTS9 promoter activation was analyzed in OUMS-27 cells.

Materials and methods

Antibodies and reagents. Mouse monoclonal antibodies against the phosphorylated NF-κB-p65 subunit (sc-33020; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), total NF-κB-p65 (sc-372; Santa Cruz Biotechnology, Inc.) and IκB-α (9242; Cell Signaling Technology, Inc., Danvers, MA, USA) were used for western blot analysis at a dilution of 1:1,000. Recombinant human IL-1β and BAY 11-7085 were purchased from R&D Systems, Inc. (Minneapolis, MN, USA) and EMD Millipore (Billerica, MA, USA), respectively. For the chromatin immunoprecipitation (ChIP) assay of the ADAMTS9 promoter region, a ChIP assay kit was used (Merck Millipore, Darmstadt, Germany). The primers used for ChIP and the conjugated oligonucleotides used for electromobility shift assays (EMSA) were purchased from Alpha DNA technologies (Montreal, Canada). A Light Shift chemiluminescence EMSA kit was purchased from Thermo Fisher Scientific (Waltham, MA, USA).

Cell cultures and cytokine treatment. The OUMS-27 human chondrosarcoma cell line was obtained from Okayama University Graduate School of Medicine Dentistry and Pharmacological Sciences (Okayama, Japan). Cells were maintained in Dulbecco's modified Eagle's medium-low glucose (Thermo Fisher Scientific) supplemented with 10% fetal calf serum (Thermo Fisher Scientific), 100 U/ml penicillin (Thermo Fisher Scientific) and 100 μg/ml streptomycin (Thermo Fisher Scientific) at 37°C in 5% CO_2. Cells were treated with or without 10 ng/ml IL-1β, and 5, 10 or 20 μg/ml BAY-117085 was added to the cultures.

Western blotting. Cell lysates were separated using 10% SDS-PAGE (Sigma-Aldrich, St. Louis, MO, USA) and transferred to polyvinylidene difluoride membranes (EMD Millipore). The membrane was treated with 5% non-fat milk (Cell Signalling Technologies, Inc., Danvers, MA, USA) for 1 h at room temperature and probed with the p-NF-κB-p65 subunit, total NF-κB-p65 and IkB-α primary antibodies overnight at 4°C. The primary antibodies were detected using horseradish peroxidase (HRP)-conjugated anti-rabbit and anti-mouse secondary antibodies (IgG; Santa

Cruz Biotechnology, Inc.), and visualized using enhanced chemiluminescence (Thermo Fisher Scientific).

ChIP assay. ChIP analysis was performed according to the manufacturer's instructions (EMD Millipore). Following treatment with IL-1β, OUMS-27 cells were fixed with 1% formaldehyde (Sigma-Aldrich) for 5 min. The cells were lysed in SDS lysis buffer (Thermo Fisher Scientific). Subsequently the chromatin was sonicated to an average size of 0.5-1 kb. Chromatin solutions were precipitated overnight at 4°C using an anti-p65 antibody. Immune complexes were recovered using a salmon sperm DNA-saturated protein A agarose gel (EMD Millipore). In order to reverse the cross-linked and immunoprecipitated chromatin, solutions were incubated at 65°C overnight. DNA was extracted using phenol/chloroform (Sigma-Aldrich) and precipitated with ethanol (Sigma-Aldrich) following proteinase K (Sigma-Aldrich) treatment. PCR was conducted in order to amplify 205 and 260 bp fragments of the ADAMTS9 promoter region (-1335/-1177), using the following PCR protocol: 96°C for 5 min and 96°C for 30 sec, followed by 30 cycles of 56°C for 30 sec and 72°C for 40 sec. The primers for ADAMTS9 promoter regions (-1335 and -1177) were obtained from Alpha DNA Technologies, and are shown in Table I. SoniGenomic DNA (EMD Millipore), following sonication, was used as a positive control and immunoprecipitated DNA-conjugated mouse IgG (EMD Millipore) was used as a negative control for the experiments.

EMSA. EMSA was performed using the LightShift Chemiluminescent EMSA kit (Thermo Fisher Scientific), according to the manufacturer's instructions. Nuclear extracts were prepared from OUMS-27 cells and probed with HRP-conjugated DNA oligos, which were homologous to the consensus NF-κB site at -1335 upstream of the ADAMTS9 promoter region. A biotin-labeled 5'GGCTGAAAGCAAGCGGAAGTGATTGAGAAATCCCT CCAG3' oligo was used. Protein-DNA complexes were separated on a 6% polyacrylamide gel using electrophoresis. A super shift assay was performed using nuclear extracts pretreated with antibodies against the NF-κB-p65 protein (as used in western blot analysis). The NF-κB competitor probe, a nonlabeled (''cold'') oligonucleotide, was added in excess to be used as a negative control, and the H4 histone protein was used as a positive control (Thermo Fisher Scientific).

Results

IL-1β-stimulated NF-κB-p65 phosphorylation is reversed by BAY 11-7085. A western blot analysis was performed in order to analyze NF-κB-p65 phosphorylation following IL-1β treatment. According to results from gel electrophoresis, the level of expression of phosphorylated NF-κB-p65 in OUMS-cells was greater following 10 min of IL-1β treatment compared with that following 5 min of treatment (Fig. 1A). Following 30 min of IL-1β treatment, phosphorylated NF-κB-p65 expression levels had decreased. In the negative control cells (no IL-1β treatment), phosphorylated NF-κB-p65 was not expressed. IκB-α was expressed in the negative control OUMS-27 cells but not in the IL-1β treated OUMS-27 cells. Following treatment with BAY-117085 (an NF-κB pathway inhibitor), the expression

Table I. Primers used in the chromatin immunoprecipitation analysis.

NF-κB consensus site in ADAMTS9 promoter	Sense (5'-3')	Antisense (3'-5')	PCR product (bp)
-1335	CCACTGAACCACCCAAGATT	GGAGTGTAAAGTTGTAGATCC	205
-1177	GGATCTACAACTTTACACTCC	TGGGGTTCTTAATCCTGCAGGTC	260
-618	GGAAAGGGAGAGAACTTTCC	TTCCAGACCATGTCCCCTCC	196
-460	GGAGGGGACATGGTCTGGAA	GGATAGCTGAGCGGCTTCTT	402
-130	AAGAAGCCGCTCAGCTATCC	CGCCAACTTTTGACTTTAGG	258

NF-κB, nuclear factor-κB; ADAMTS9, a disintegrin-like and metalloproteinase with thrombospondin type 1 motif 9 ; bp, base pairs.


Figure 1. (A) p65 phosphorylation. OUMS-27 cells were stimulated with 10 ng/ml IL-1β. Total cell extracts were immunoblotted with anti-phospho-p65, anti-total IκB-α and total NF-κB-p65 antibodies. (B) Effect of the NF-κB inhibitor, BAY 11-7085, on NF-κB-p65 phosphorylation. OUMS-27 cells were treated with 10 ng/ml IL-1β for 10 min. IL-1β, interleukin-1β; NF-κB, nuclear factor-κB; Con, negative control; IκB, nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor.

of phosphorylated NF-κB-p65 in the cells decreased, in a time-dependent manner. By contrast, the level of phosphorylated NF-κB-p65 expression in the negative control cells was comparable to that of total NF-κB expression (Fig. 1B).

NF-κB-p65-binding sites in the ADAMTS9 promoter. A previous investigation demonstrated that NFATc1 binding consensus sites may activate ADAMTS9 gene expression (2). In the present study, cloned human ADAMTS9 gene sequences were analyzed in order to investigate the involvement of other putative transcription factor binding sites in ADAMTS9 gene expression. The consensus DNA-binding sequence of NF-κB is GGGRNNYYCC (N = any base, R = purine, and Y = pyrimidine) (11). DNA sequences that were highly homologous to the consensus DNA-binding sequence of NF-κB were identified in the ADAMTS9 genome data base (Fig. 2). In the present study, two sequences located -1335 and -1177 bp upstream of the transcription start site of ADAMTS9 were used for further analysis due to the ChIP experiments. Other sites defined as -130, -460 and -618 did not exhibit effective NF-κB binding of ADAMTS9, according to the ChIP experiments (data not shown). Immunoprecipitation analysis was performed and the amplification of potential consensus sites was assessed via PCR amplification using the primers in Table I.

Figure 2. DNA sequences homologous to the consensus DNA-binding sites of NF-κB and their positions in the ADAMTS9 promoter region. Primers targeting the potential consensus sites are indicated below the genes. Electrophoresis was used to confirm the amplification of consensus sites using the primers in Table I. NF-κB, nuclear factor-κB.


Figure 3. Activation of the ADAMTS9 promoter region. OUMS-27 cells were treated with 10 ng/ml IL-1β for 20 min and then fixed with 1% formaldehyde for 10 min. A chromatin immunoprecipitation assay was performed using an anti-p65 antibody. DNA was PCR amplified using ADAMTS9 promoter-specific primers. IL-1β, Interleukin-1β; ADAMTS9, a disintegrin-like and metalloproteinase with thrombospondin type 1 motif 9; ChIP, chromatin immunoprecipitation; NF-κB, nuclear factor-κB; IgG, immunoglobulin G; H4, histone.


Figure 4. Confirmation of NF-κB-binding sites in the ADAMTS9 promoter region. OUMS-27 cells were treated with IL-1β for 20 min. An electromobility shift assay was conducted using biotin-labeled primers containing each of the homologous NF-κB binding sites. DNA extracts from IL-1β-treated OUMS-27 cells were pretreated with antibodies against Rel family proteins. NF-κB, nuclear factor-κB; IL-1β, Interleukin-1β.

Following 20 min of OUMS-27 cell treatment with IL-1β, ChIP analysis suggested that NF-κB successfully bound with the ADAMTS9 promoter consensus sites, -1335 and -1177 (Fig. 3). However, NF-κB did not bind with the ADAMTS9 promoter #1 consensus site (-1335) in the negative control OUMS-27 cells (no IL-1β treatment). IgG was used as a negative control and H4 histone protein was used as a positive control for the experiment. For promoter #2, there was

decreased binding of NF-κB in the IL-1β untreated cells, as compared with the treated cells at -1177 bp upstream of the ADAMTS9 promoter (Fig. 3).

In order to confirm the presence of NF-κB binding sites in the ADAMTS9 promoter region an EMSA assay was performed. A supershift assay suggested that, following IL-1β treatment, NF-κB bound to ADAMTS9 promotors in OUMS-27 cells. However, in cells not treated with IL-1β, NF-κB did not bind to ADAMTS9 promotors. By contrast, in negative control cells, using a cold NF-κB competitor, there was no evidence of NF-κB binding to the ADAMTS9 promoters. In the positive control cells, only a 'free probe' was expressed (Fig. 4).

Discussion

The results of the present study suggested that the human ADAMTS9 promoter region exhibits NF-κB binding elements and may be a target gene for NF-κB gene expression. IL-1β-induced NF-κB is capable of binding with ADAMTS9 promoters in OUMS-27 chondrosarcoma cells. ADAMTSs are secreted proteinases, which are involved in cell adhesion, proteolytic shedding and cell signaling (12).

The ADAMTS9 gene is localized to chromosome 3p14.2 and is the most highly conserved member of the ADAMTS family. ADAMTS9 cleaves versican and aggrecan proteins, and may therefore be termed aggrecan. Previous studies have indicated that aggrecanases are associated with the development of a number of diseases, due their involvement in cell development, angiogenesis, cancer and inflammatory processes (13-15). In osteoarthritis and rheumatoid arthritis, ADAMTS9 is involved in inflammatory responses associated with cartilage damage (13,15). Therefore, elucidation of the regulatory mechanisms underlying ADAMTS9 expression and activation is required. A number of studies have revealed that various signaling pathways, such as the mitogen-activated protein kinases (MAPK) pathway, are associated with the regulation of ADAMTS9 gene expression (3-5). ADAMTS9 gene expression was found to be downregulated following treatment with SB600125 and BAY 11-7085, which are inhibitors of MAPK and NF-κB, respectively (4,6). The phosphoinositide 3-kinase signaling pathway does not appear to be associated with ADAMTS9 gene expression (3). There is evidence to suggest that ADAMTS9 expression may be regulated by IL-1β and TNF-α treatment (4). A previous study demonstrated that, following IL-1β treatment of isolated chondrosarcoma and chondrosarcoma cells, ADAMTS9 expression was induced to a greater degree than that of all other aggrecanase genes (4). IL-1β may activate the expression of a number of inflammation-associated transcription factors. A previous study demonstrated that the transcription factor, NFATc1, is capable of activating the expression of ADAMTS9 following IL-1β treatment in human chondrocytes (5). The results of the present study suggested that NF-κB activation, following IL-1β treatment, is associated with ADAMTS9 expression in OUMS 27 cells.

NF-κB is involved in the activation of a number of genes that encode adhesion molecules, such as E-selectin. These molecules mediate leukocyte tethering and rolling, which is involved in acute and chronic inflammatory processes that are associated with inflammatory injury and rheumatoid arthritis (16,17). The present study demonstrated that the ADAMTS9 promoter region contains five NF-κB consensus binding sites at -130, -460, -618, -1177 and -1335 bp. A previous study suggested that NF-κB phosphorylation may be induced following IL-1β treatment in Jurkat cell lines derived from an immortalized line of T lymphocytes and HEK293 (human embryonic kidney cells) (7). In the present study, NF-κB-p65 was phosphorylated following IL-1β treatment of OUMS-27 cells. The results suggest that NF-κB-p65 phosphorylation may induce the binding of NF-κB-p65 to specific consensus sites of the ADAMTS9 promoter region at locations -1177 and -1335 bp, following treatment with IL-1β. According to the electrophoresis gel image (Fig. 3), this bond was most prominent at location -1335 bp, compared with location -1177 bp of the ADAMTS9 promoter region. By contrast, in negative control OUMS-27 cells, NF-κB did not bind to the ADAMTS9 promoter region.

In conclusion, the results of the present study suggested that the human ADAMTS9 promoter region exhibits NF-κB consensus sites, which are potential targets for NF-κB transcription factor binding. IL-1β-induced NF-κB-p65 subunit binding to the ADAMTS9 promoter region in OUMS-27 cells. The present study provides a novel approach for ADAMTS9 gene-targeted therapy and ADAMTS9 inhibition. These results may be suitable for the development of treatment for a number of pathological conditions, including cartilage injury.

Acknowledgements

References

1. Tortorella MD, Burn TC, Pratta MA, et al: Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 284: 1664-1666, 1999.
2. Apte SS: A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 36: 981-985, 2004.
3. Uysal S, Ünal ZN, Erdoğan S, et al: Augmentation of ADAMTS9 gene expression by IL-1β is reversed by NF-ϰB and MAPK inhibitors, but not PI3 kinase inhibitors. Cell Biochem Funct 31: 539-544, 2013.
4. Demircan K, Hirohata S, Nishida K, et al: ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes. Arthritis Rheum 52: 1451-1460, 2005.
5. Yaykasli KO, Oohashi T, Hirohata S, Hatipoglu OF, Inagawa K, Demircan K and Ninomiya Y: ADAMTS9 activation by interleukin 1 beta via NFATc1 in OUMS-27 chondrosarcoma cells. and in human chondrocytes. Mol Cell Biochem 323: 69-79, 2009.
6. Xu YX, Pindolia KR, Janakiraman N, Chapman RA and Gautam SC: Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-κB DNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol 11: 49-62, 1997.
7. Chen D, Li X, Zhai Z and Shu HB: A novel zinc finger protein interacts with receptor-interacting protein (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B activation. J Biol Chem 277: 15985-15991, 2002.
8. Cogswell JP, Godlevski MM, Wisely GB, et al: NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol 153: 712-723, 1994.
9. Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12: 86, 2013.

10. Barnes PJ and Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997.
11. Hayden MS and Ghosh S: Signaling to NF-kappaB. Genes Dev 18: 2195-2224, 2004.
12. Bret C, Hose D, Reme T, *et al*: Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment. Exp Hematol 39: 546-557, 2011.
13. Demircan K, Yonezawa T, Takigawa T, *et al*: ADAMTS1, ADAMTS5, ADAMTS9 and aggrecanase-generated proteoglycan fragments are induced following spinal cord injury in mouse. Neurosci Lett 544: 25-30, 2013.
14. Lin EA, Liu CJ: The role of ADAMTSs in arthritis. Protein Cell 1: 33-47, 2010.
15. Kevorkian L, Young DA, Darrah C, *et al*: Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 50: 131-141, 2004.
16. Zheng X, Zhu S, Chang S, *et al*: Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: Role of NF-kappa B signaling. Eur J Pharmacol 25: S0014-2999, 2013.
17. Choi YJ, Lee WS, Lee EG, Sung MS and Yoo WT: Sulforaphane inhibits IL-1β-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of MMPs, COX-2, and PGE2. Inflammation 37: 1496-1503, 2014.